STRATEGIES TO EXTEND PLATELET STORAGE

这些研究的主要目的是确定血小板（pit）是否可以保存更长时间 比目前许可的5天。此外，窖池贮存的时间是否视乎窖池的种类而定 储存的产品（单采坑，从富坑血浆（PRP）或血沉棕黄制备的坑浓缩物 包被（BC）、储存前混合PRP凹坑浓缩物或减少病原体的单采术或BC凹坑），以及 用于存储的介质;即，血浆或储存溶液。这四个关键问题将被... 在我们的研究中有：1）使用单采术程序收集凹坑的方法与准备- 从全血中提取浓缩物是否影响储存时间？2)是否进行了坑孔预存池化， 中心影响坑的生存能力？3)坑存储解决方案是否允许坑存储的时间长于坑存储在 等离子体？以及4）病原体减少的凹坑是否可以与非病原体类似地储存延长的时间段 减少坑？尽管将进行体外试验以记录储存后的凹坑计数以及VA， 一系列测定以确定贮藏后的窖功能、代谢和细胞凋亡， 延长储存的凹坑将基于正常志愿者和缺血性脑卒中患者的体内测量。 患者具体而言，放射性标记的窝恢复和存活测量延长储存的自体 将使用正常志愿者的坑确定所有类型坑产品的储存后坑活力 储存在血浆中与储存溶液中。对于储存时间超过8天和/或 在储存溶液中，在血小板减少患者中的输血研究将用于评估Pit存活率， 通过测量输血后供者窝的放射性标记恢复和存活率来评估其有效性。交替- 实际上，患者对输血供体小窝的反应将通过测量输血后小窝来确定， 增量、校正计数增量和下一次输血的天数。坑函数（即，止血） 将通过小窝计数与出血时间测量来监测长期储存的供体小窝的输血- 通过放射性铬标记的粪便失血研究。 在这些研究的结论，我们应该知道多久每一种类型的坑可以存储在血浆中 或Plasmalyte，每种类型的坑的相对优点，以及扩展存储的坑是否都是可行的 并且对血小板减少症患者有效。

The primary objective of these studies is to determine whether platelets (pits) can be stored for longer than the currently-licensed 5 days. Furthermore, does the duration of pit storage depend on the type of pit product being stored (apheresis pits, pit concentrates prepared from pit-rich plasma (PRP), or from buffy coats (BC), pre-storage pooled PRP pit concentrates, or pathogen-reduced apheresis or BC pits), and the medium used for storage; i.e., plasma or a storage solution. The four critical questions that will be ad- dressed in our studies are: 1) does the method of pit collection using apheresis procedures versus prepar- ing pit concentrates from whole blood influence storage duration?; 2) does pre-storage pooling of pit con- centrates affect pit viability?; 3) do pit storage solutions allow pits to be stored longer than pits stored in plasma?; and 4) can pathogen-reduced pits be stored for extended time periods similar to non-pathogen reduced pits? Although in vitro tests will be performed to document post-storage pit counts as well as a va- riety of assays to determine post-storage pit function, metabolism and apoptosis, the post-storage quality of the extended stored pits will be based on in vivo measurements in normal volunteers and thrombocytopenic patients. Specifically, radiolabeled pit recovery and survival measurements of extended stored autologous pits in normal volunteers will be used to determine post-storage pit viability for all types of pit products stored in plasma versus a storage solution. For pits that are stored for longer than 8 days and/or are stored in a storage solution, transfusion studies in the thrombocytopenic patients will be used to evaluate pit viabil- ity by measuring the radiolabeled recovery and survival of the donors' pits following transfusion. Alterna- tively, patient responses to transfused donor pits will be determined by measuring post-transfusion pit in- crements, corrected count increments, and days-to-next transfusion. Pit function (i.e., hemostasis) following the transfusion of extended stored donor pits will be monitored by pit count versus bleeding time measure- ments and by radiochromium-labeled stool blood loss studies. At the conclusion of these studies, we should know how long each type of pits can be stored in plasma or Plasmalyte, the relative merits of each type of pits, and whether the extended stored pits are both viable and functional when given to thrombocytopenic patients.